AACR: MD Anderson team uncovers new target for blocking mutant KRAS and p53 in pancreatic cancer fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.
Researchers identify surface protein as a new osteosarcoma therapeutic target for antibody-drug conjugates miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Credit: MD Anderson Cancer Center
HOUSTON Early phase clinical trials conducted by researchers from The University of Texas MD Anderson Cancer Center show promising results for patients with RET fusion-positive cancers, high-grade (HGG) and low-grade glioma (LGG) and ovarian cancer.
The results, presented today at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021, showcase the researchers ongoing efforts to advance clinical studies and expand potential indications of approved drugs to develop a platform for more effective treatments and to improve patient outcomes.
FDA-approved selpercatinib shows clinical benefits for RET fusion-positive cancers beyond lung and thyroid cancers (Abstract CT011)
Scientists believe that the groundbreaking mRNA technology behind the COVID-19 vaccines could unlock treatments for deadly diseases, including cancer and HIV.